Stephen Buksh, MD
Internal Medicine · Euless, TXNPI 1427053396
Payments from drug & device makers
Across 238 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$710
- GSK$475
- Novo Nordisk$431
- Abbott$293
- Amgen$234
- AstraZeneca$197
- plus $2K from 31 others
What the payments were for
- Food & beverage$4,021100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 46 | $710 |
| GSK | 28 | $475 |
| Novo Nordisk | 28 | $431 |
| Abbott | 15 | $293 |
| Amgen | 13 | $234 |
| AstraZeneca | 11 | $197 |
| Boehringer Ingelheim | 10 | $188 |
| Pfizer | 11 | $184 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $167 |
| Novartis | 9 | $164 |
| Bayer | 8 | $143 |
| Lilly USA, LLC | 5 | $104 |
| Astellas Pharma US Inc | 6 | $98 |
| Johnson & Johnson | 5 | $77 |
| Orexo US, Inc. | 4 | $71 |
| Exact Sciences | 2 | $41 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Sumitomo Pharma America, Inc. | 2 | $28 |
| Eisai Inc. | 2 | $27 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Inari Medical, Inc. | 1 | $24 |
| Silk Road Medical, Inc. | 1 | $24 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Seqirus USA Inc | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Antares Pharma, Inc. | 1 | $16 |
| Boston Scientific | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $14 |
| Neuronetics, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $13 |
| Nalpropion Pharmaceuticals LLC | 1 | $12 |
How this compares
$4,021 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 122 | $173,993 |
| JardianceEmpagliflozin | 134 | $135,174 |
| EliquisApixaban | 130 | $132,482 |
| MounjaroTirzepatide | 97 | $112,300 |
| TrulicityDulaglutide | 75 | $99,622 |
| XareltoRivaroxaban | 51 | $66,106 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $52,747 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 103 | $24,677 |
| FarxigaDapagliflozin Propanediol | 22 | $22,857 |
| MyrbetriqMirabegron | 23 | $19,612 |
| JanuviaSitagliptin Phosphate | 23 | $18,117 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 27 | $15,127 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $12,536 |
| SymbicortBudesonide/Formoterol Fumarate | 34 | $10,919 |
| TradjentaLinagliptin | 12 | $9,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $104 | $211,922172 claims |
| Novo NordiskOzempic | $431 | $173,993122 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat | $188 | $166,773187 claims |
| PfizerEliquis | $184 | $132,482130 claims |
| Johnson & JohnsonXarelto | $77 | $66,10651 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $475 | $65,28358 claims |
| AstraZenecaFarxiga, Symbicort | $197 | $33,77656 claims |
| Astellas Pharma US IncMyrbetriq | $98 | $19,61223 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $7,438716 claims |
| AbbVieSynthroid | $710 | $4,65062 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Euless
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.